Progress advance in the application of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
10.3760/cma.j.issn.1673-4181.2019.03.010
- VernacularTitle:免疫检查点抑制剂在非小细胞肺癌治疗中的应用进展
- Author:
Lianmin ZHANG
1
;
Dongsheng YUE
;
Zhenfa ZHANG
;
Changli WANG
Author Information
1. 天津医科大学肿瘤医院肺部肿瘤科
- Keywords:
Non-small cell lung cancer;
Immunotherapy;
Immune-checkpoint inhibitors;
Neoadjuvant therapy;
Pseudo progress
- From:
International Journal of Biomedical Engineering
2019;42(3):239-244
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignant tumor in the world. In order to improve the survival rate of patients with advanced lung cancer, more effective treatment methods are needed,in which immunotherapy has a broad therapeutic prospect. In recent years, immune-checkpoint inhibitors have received extensive attention in the treatment of lung cancer. Significant progress has been made in the development of a variety of first-line and second-line treatments, and significant advances have been made in the treatment of advanced lung cancer. With the successful application of immune-checkpoint inhibitors, neoadjuvant therapy has attracted extensive attention. In addition, the successful application of combined therapies such as immune combined immunization, immune combined tyrosine kinase inhibitor (TKI) and immune combined chemotherapy improved the survival rate of patients to some extent. However, pseudo progression and drug resistance has become a non-negligible problem in the immunotherapy of non-small cell lung cancer, which is worthy of further study. Although immune-checkpoint inhibitors have once again brought attention to tumor immunotherapy, their side effects are also worthy of attention. The recent advances in the application of immune-checkpoint inhibitors in lung cancer were summarized in order to provide a theoretical basis for its clinical application.
